Dismantling the immune-metabolic barrier in TP53-mutant hematologic malignancies

Tumor protein 53 ( TP53 ) mutations, long recognized as harbingers of poor prognosis, drive treatment failure in hematologic malignancies by erecting two mutually reinforcing defense systems. Immune evasion is effected through silencing of death-receptor signaling, crippled antigen presentation, and establishment of a T-cell-exclusionary microenvironment, while a parallel metabolic shield fortifies cells against oxidative, proteotoxic, and replicative stress. Here, we propose that immune evasion and metabolic fortification do not operate in complete isolation, but rather as an integrated defense network with emergent crosstalk nodes. We dissect how the spectrum of TP53 mutations dictates the configuration of this barrier, analyze why mono-modal therapies, from chimeric antigen receptor (CAR)-T cells and bispecific antibodies to chemotherapy and BCL-2 homology 3 (BH3) mimetics, have shown limited efficacy to date, and outline a roadmap for rationally designed, multi-node therapeutic combinations that may convert these integrated defenses into selective vulnerabilities. This synthesis offers a conceptual framework that may serve as both a mechanistic compass and a translational guide for tackling the high-risk genotypes in leukemia, lymphoma, and myelodysplastic syndromes (MDS).